The findings from the aforementioned study are consistent with the results of our research, suggesting that the target proteins CDK2, CCND1, and E2F1 may serve as potential biomarkers and crucial therapeutic targets in lung cancer. This evidence concerns the gene E2F1 and lung carcinoma.